Literature DB >> 30683759

Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results.

Blake Gilks1, Naveena Singh2, Steffen Böhm3, Nhu Le4, Michelle Lockley5, Elly Brockbank6, Asma Faruqi2, Ian Said2,7, Arjun Jeyarajah6, Rekha Wuntakal8.   

Abstract

OBJECTIVE: The Chemotherapy Response Scoring (CRS) system was developed to enable reproducible reporting of histologic tumor response in interval debulking specimens following neoadjuvant chemotherapy in advanced stage tubo-ovarian high-grade serous carcinoma. This prognostic biomarker has been included in ovarian cancer pathology reporting guidelines (International Collaboration on Cancer Reporting, College of American Pathologists) and in the upcoming European Society for Medical Oncology-European Society of Gynaecological Oncology (ESMO-ESGO) guidelines for ovarian cancer management. We present follow-up data on the CRS validation initiatives and suggest research with novel therapeutic agents incorporating this biomarker.
METHODS: The cohort on whom CRS was originally developed was analyzed after an extended follow-up of an additional 36 months. The CRS histopathologic scoring system was applied to omental sections obtained at interval surgery from all 80 patients. Progression-free and overall survival were re-calculated.
RESULTS: After a median follow-up of 4.3 years the CRS score predicted progression-free survival with an HR of 0.39 (95% CI 0.21 to 0.70), p = 0.002 adjusted for age, stage, and debulking status (median 1.08 vs 2.27 years for CRS1/2 vs CRS3). CRS was also predictive of overall survival with an HR of 0.17 (95% CI 0.07 to 0.44), p = 0.0002 adjusted for age, stage, and debulking status (median 2.55 vs 5.47 years for CRS1/2 vs CRS3).
CONCLUSION: CRS3 is a reproducible prognostic biomarker for improved progression-free and overall survival in stage 3C or 4 tubo-ovarian high-grade serous carcinoma after neoadjuvant chemotherapy. The score, obtained at interval debulking surgery, can help facilitate research and biomarker driven first-line treatment of patients with advanced ovarian cancer. © IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  CRS; biomarker; chemotherapy response; ovarian cancer; personalised therapy

Year:  2019        PMID： 30683759     DOI： 10.1136/ijgc-2018-000092

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN： 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  Primary and metastatic peritoneal surface malignancies.

Authors:  Delia Cortés-Guiral; Martin Hübner; Mohammad Alyami; Aditi Bhatt; Wim Ceelen; Olivier Glehen; Florian Lordick; Robert Ramsay; Olivia Sgarbura; Kurt Van Der Speeten; Kiran K Turaga; Manish Chand
Journal:  Nat Rev Dis Primers       Date:  2021-12-16       Impact factor: 52.329

2.  Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.

Authors:  Leonardo Rundo; Lucian Beer; Lorena Escudero Sanchez; Mireia Crispin-Ortuzar; Marika Reinius; Cathal McCague; Hilal Sahin; Vlad Bura; Roxana Pintican; Marta Zerunian; Stephan Ursprung; Iris Allajbeu; Helen Addley; Paula Martin-Gonzalez; Thomas Buddenkotte; Naveena Singh; Anju Sahdev; Ionut-Gabriel Funingana; Mercedes Jimenez-Linan; Florian Markowetz; James D Brenton; Evis Sala; Ramona Woitek
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

3.  A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy.

Authors:  Yanping Zhong; Jinsong Liu; Xiaoran Li; Shannon N Westin; Anais Malpica; Barrett C Lawson; Sanghoon Lee; Bryan M Fellman; Robert L Coleman; Anil K Sood; Nicole D Fleming
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

4.  A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?

Authors:  Barrett C Lawson; Elizabeth D Euscher; Roland L Bassett; Jinsong Liu; Preetha Ramalingam; YanPing Zhong; Nicole D Fleming; Anais Malpica
Journal:  Am J Surg Pathol       Date:  2020-02       Impact factor: 6.298

5.  Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy.

Authors:  M Liontos; A Andrikopoulou; K Koutsoukos; C Markellos; E Skafida; O Fiste; M Kaparelou; N Thomakos; D Haidopoulos; A Rodolakis; M A Dimopoulos; F Zagouri
Journal:  J Ovarian Res       Date:  2021-11-01       Impact factor: 4.234

Review 6.  Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Angela Santoro; Antonio Travaglino; Frediano Inzani; Patrizia Straccia; Damiano Arciuolo; Michele Valente; Nicoletta D'Alessandris; Giulia Scaglione; Giuseppe Angelico; Alessia Piermattei; Federica Cianfrini; Antonio Raffone; Gian Franco Zannoni
Journal:  Diagnostics (Basel)       Date:  2022-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.